ArticleJournal of translational medicine2026
Patient-specific lung cancer tumoroids recapitulate the tumor microenvironments for functional evaluation of therapeutic responses and immune-stromal interactions.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- 3D models for cancer-microbe interaction studiesFrontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor heterogeneity and the complexity of the tumor microenvironment (TME) drive therapeutic resistance in lung cancer, highlighting the critical need for experimental models that faithfully recapitulate tumor-stroma-immune interactions.
methodsWe developed patient-specific lung cancer tumoroid (LCT) models by integrating lung cancer organoids (LCOs), cancer-associated fibroblasts (CAFs) and immune cells isolated from single tumor tissue sources using a modular, transwell-based culture platform. The model supports cryopreservation and reproducible reconstruction of cellular components. Multimodal assessments, including histological characterization, dose-response pharmacologic profiling, immune profiling, and transcriptomic analyses, were performed across diverse co-culture configurations to evaluate patient-specific TME features and treatment-associated responses.
resultsThe LCT models successfully recapitulated key structural and cellular features of native TMEs, demonstrating high reproducibility across patient samples. Functional analyses revealed tumor-intrinsic heterogeneity in responses to chemotherapy and chemo-immunotherapy. CAF integration altered therapeutic responses and was associated with reduced immune activation and cytotoxic efficacy in selected models, suggesting stromal contributions to treatment resistance. Transcriptomic analyses showed that reconstructed TMEs preserved patient-specific stromal and immune programs associated with therapeutic responsiveness, including transcriptional features linked to clinical outcomes in independent immunotherapy-treated cohorts.
conclusionsThis patient-specific LCT model provides a scalable and translationally relevant approach for the ex vivo reconstruction of native TMEs, facilitating the functional interrogation of tumor-stroma-immune interactions. By capturing heterogeneous stromal responses, this platform offers a valuable tool for investigating therapeutic resistance and supports the further development of precision immune-oncology and patient-tailored therapeutic strategies in lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.